, Volume 65, Issue 3–4, pp 253–256 | Cite as

Validated Enantioselective LC Method, with Precolumn Derivatization with Marfey’s Reagent, for Analysis of the Antiepileptic Drug Pregabalin in Bulk Drug Samples

  • A. S. Jadhav
  • D. B. Pathare
  • M. S. Shingare
Limited Short Communication


An enantioselective high-performance liquid chromatographic method, with precolumn derivatization with Marfey’s chiral reagent, sodium 2,4-dinitro-5-fluorophenyl-l-alanine amide, has been developed for resolution of the enantiomers of a new antiepileptic drug, pregabalin, in the bulk drug. The diastereomers of the pregabalin enantiomers were resolved to baseline on a reversed-phase ODS column with a 60:40 (v/v) mixture of aqueous 0.2% triethylamine (pH adjusted to 3.5 with dilute orthophosphoric acid) and acetonitrile as mobile phase. Resolution between the diastereomers was not less than five. The method was extensively validated and proved to be robust. The calibration plot was indicative of an excellent linear relationship between response and concentration over the range 750 (LOQ) to 7,500 ng L−1 for the R enantiomer. The limits of detection and quantification of the R enantiomer were 250 and 750 ng L−1, respectively, for an injection volume of 10 μL. Recovery of the R enantiomer from bulk drug samples of pregabalin ranged from 97.5 to 101.76%. Solutions of pregabalin in water and in the mobile phase were found to be stable for at least 48 h. The method was found to be suitable and accurate for quantitative determination of the R enantiomer in the bulk drug. It can be also used to test the stability of samples of pregabalin.


Column liquid chromatography Enantioselective liquid chromatography Diastereomers Marfey’s reagent Pregabalin 



The authors wish to thank the management of Wockhardt Group, Mumbai, India, for donation of the drugs. We would also like to thank the Process research group for important discussions during this work.


  1. 1.
    Warner G, Figgitt DP (2005) CNS Drugs 19:265–272Google Scholar
  2. 2.
    Donald JA (2003) Burger’s medicinal chemistry and drug discovery, 6th edn. Wiley, New Jersey, pp 312–313Google Scholar
  3. 3.
    Khalid H, Josemir WS (2006) Seizure 15:73–78. doi: 10.1016/j.seizure.2005.11.005Google Scholar
  4. 4.
    Frampton JE, Foster RH (2006) CNS Drugs 20:685–693Google Scholar
  5. 5.
    Sahajwalla CG (2004) New drug development. Marcel Dekker, New York, pp 421–426Google Scholar
  6. 6.
    Thomas EB, Scott RPW (1998) Chiral chromatography. Wiley, New York, pp 23–26Google Scholar
  7. 7.
    Benjamin JD, Magan KH, Julie AC, Simon MP, Janet KC, Andrew AS, Robert WM, Benedetta CS (2006) J Chromatogr B 832:114–120. doi: 10.1016/j.jchromb.2005.12.046Google Scholar
  8. 8.
    Zhiqiong Chen, Yu Yu, Longjiangi Li (2005) J Sep Sci 28:193–196. doi: 10.1002/jssc.200401804Google Scholar
  9. 9.
    Hiroyuki F, Hideyuki Y, Hitoshi N, Masatoshi Y (2005) Anal Sci 21:1121–1124. doi: 10.2116/analsci.21.1121Google Scholar
  10. 10.
    Antal P, Anita A, Erika V, Drik T, Laszlo L, Ferenc F, Daniel WA (2004) J Chromatogr A 1031:171–180. doi: 10.1016/j.chroma.2003.08.070Google Scholar
  11. 11.
    Berry D, Millington C (2005) Ther Drug Monit 27:451–456CrossRefGoogle Scholar
  12. 12.
    Vermeij TAC, Edelbroek PM (2004) J Chromatogr B 810:297–303. doi: 10.1016/j.jchromb.2004.08.018Google Scholar
  13. 13.
    Coutrim MX, Nakamura LA, Collins CH (1993) Chromatographia 37:185–190CrossRefGoogle Scholar

Copyright information

© Friedr. Vieweg & Sohn Verlag/GWV Fachverlage GmbH 2006

Authors and Affiliations

  • A. S. Jadhav
    • 1
  • D. B. Pathare
    • 1
  • M. S. Shingare
    • 1
  1. 1.Department of ChemistryDr B. A. Marathawada UniversityAurangabadIndia

Personalised recommendations